Zenara's Generic Ertugliflozin Receives Approval in the U.S.
FDA Confirms Paragraph IV Patent Litigation for Ertugliflozin
Ertugliflozin Reduces Likelihood of Insulin Initiation in Insulin-Naive Patients
Late to the party against its SGLT2 diabetes rivals, Merck & Co.'s Steglatro has also tracked way behind in the class' growing presence in heart failure. Now, the drugmaker has posted new data showing Steglatro could, in fact, show benefits in that indication—but it's a limited window into the future.
KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries. The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is composed of a composite of CV death, nonfatal myocardial infarction or nonfatal stroke, compared to placebo.
Merck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data won’t help it get on their level.
Merck and Pfizer’s Steglatro, late to the SGLT2 party, has been working to catch up to its in-class rivals, which already bear heart-helping approvals. But its cardiovascular outcomes data won’t help it get on their level.
The National Institute of Care and Health Excellence (NICE) has recommended MSD’s Steglatro (ertugliflozin) for use within the NHS, for the treatment of adults with type II diabetes.
Anti-diabetes medications in the sodium-glucose cotransporter-2 (SGLT2) inhibitor class will soon come with a new warning on their labels after a directive from the Drug Controller General of India (DGCI) over potential risk of acute pancreas inflammation and a rare but serious genital infection. SGLT2 inhibitors, medicines that lower blood sugar by causing kidneys to remove sugar from the body through urine, include drugs such as canagliflozin, dapagliflozin, empagliflozin and ertugliflozin.